Clinical study of Jinshuibao Tablets combined with captopril in treatment of chronic renal failure
Objective To analyze the clinical efficacy of Jinshuibao Tablets combined with captopril in treatment of chronic renal failure.Methods A total of 116 patients with chronic renal failure admitted to Nantong Hospital of Traditional Chinese Medicine from December 2020 to August 2023 were selected and divided into control group and treatment group according to random number table method,with 58 patients in each group.Patients in the control group were po administered with Captopril Tablets,25 mg/time,3 times daily.Patients in the treatment group were po administered with Jinshuibao Tablets on the basis of the control group,5 tablets/time,3 times daily.Both groups were treated for 8 weeks.The clinical efficacy of the two groups was observed.The main symptom score,renal function index(Scr),24 h urinary protein quantity(24 h UP),urea nitrogen(BUN),endogenous creatinine clearance(Ccr)]and serum levels of angiotensin Ⅱ(AngⅡ),tumor necrosis factor-α(TNF-α),matrix metalloproteinase-9(MMP-9)and fibroblast growth factor 23(FGF-23)were compared between the two groups before and after treatment.Results After treatment,the total effective rate of the treatment group was 93.10%,which was significantly higher than that of the contro l group(79.31%,P<0.05).After treatment,the scores of the main symptoms(fatigue and weakness,lumbago and knee weakness,shortness of breath and lazy speech,eating less and being lazy)were significantly decreased in both groups compared with be fore treatment(P<0.05).After treatment,the main symptom score of the treatment group was lower than that of the control group(P<0.05).After treatment,Scr,24 h UP,and BUN were significantly decreased,but Ccr was significantly increased in both groups(P<0.05).After treatment,renal function index improved more significantly in treatment group(P<0.05).After treatment,serum levels of AngⅡ,TNF-α,MMP-9,and FGF-23 in 2 groups were significantly decreased(P<0.05).After treatment,the levels of AngⅡ,TNF-α,MMP-9,and FGF-23 in the treatment group were lower than those in the control group(P<0.05).Conclusion Jinshuibao Tablets combined with captopril has a definite effect in treatment of chronic renal failure,and can effectively reduce the symptoms of patients on the basis of good drug safety,correct the inflammatory and metabolic disorders of the body,inhibit renal tubule fibrosis,and improve renal function,which is worthy of clinical application.
Jinshuibao TabletsCaptopril Tabletschronic renal failureScr24 h UPBUNCcrFGF-23inflammatory reaction
NETL
NSTL
万方数据
